

Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults

Lida Teng, Akiko Mizukami, Cheryl Ng, Nikolaos Giannelos, Desmond Curran, Tomohide Sato, Christa Lee, Taizo Matsuki

Herpes Zoster (Shingles)


Shingles is caused by reactivation of the chickenpox virus, and commonly presents as a painful rash that goes away in 4–6 weeks. However, some patients experience complications such as persistent pain, even after the rashes subside.



Older people are most commonly affected



Shingles and its complications can be prevented by vaccination



We assessed the potential public health impact and cost-effectiveness of the recombinant zoster vaccine (RZV) versus no vaccine in Japanese adults aged 65 years



A previously used mathematical model was updated with the latest information on vaccine price, and vaccine efficacy and waning



The study showed that the **RZV is expected to substantially decrease the number of cases of shingles and its complications**, and it is **cost-effective** compared with no vaccination in Japanese adults aged 65 years.

This information may be used by policymakers when assessing the value of RZV for vaccination policies in Japan.

